ATE397925T1 - Cis-imidazoline als mdm2-hemmer - Google Patents
Cis-imidazoline als mdm2-hemmerInfo
- Publication number
- ATE397925T1 ATE397925T1 AT02796582T AT02796582T ATE397925T1 AT E397925 T1 ATE397925 T1 AT E397925T1 AT 02796582 T AT02796582 T AT 02796582T AT 02796582 T AT02796582 T AT 02796582T AT E397925 T1 ATE397925 T1 AT E397925T1
- Authority
- AT
- Austria
- Prior art keywords
- imidazoline
- cis
- mdm2 inhibitors
- mdm2
- inhibitors
- Prior art date
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34172901P | 2001-12-18 | 2001-12-18 | |
| US39087602P | 2002-06-21 | 2002-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397925T1 true ATE397925T1 (de) | 2008-07-15 |
Family
ID=26992633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02796582T ATE397925T1 (de) | 2001-12-18 | 2002-12-09 | Cis-imidazoline als mdm2-hemmer |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6617346B1 (de) |
| EP (1) | EP1463501B1 (de) |
| JP (1) | JP4361798B2 (de) |
| KR (1) | KR100640707B1 (de) |
| CN (1) | CN1604778A (de) |
| AR (1) | AR037882A1 (de) |
| AT (1) | ATE397925T1 (de) |
| AU (1) | AU2002361986B2 (de) |
| BR (1) | BR0215156A (de) |
| CA (1) | CA2468783A1 (de) |
| DE (1) | DE60227108D1 (de) |
| ES (1) | ES2307822T3 (de) |
| MX (1) | MXPA04005880A (de) |
| PA (1) | PA8561801A1 (de) |
| PE (1) | PE20030717A1 (de) |
| PL (1) | PL370909A1 (de) |
| RU (1) | RU2312101C2 (de) |
| TW (1) | TW200301696A (de) |
| UY (1) | UY27586A1 (de) |
| WO (1) | WO2003051360A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| CA2528096C (en) * | 2003-06-17 | 2011-09-13 | F. Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
| MXPA06013246A (es) * | 2004-05-18 | 2007-02-08 | Hoffmann La Roche | Nuevas imidazolinas cis. |
| US8022063B2 (en) * | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
| US7893278B2 (en) * | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| SG176463A1 (en) | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| EA019566B1 (ru) * | 2005-02-22 | 2014-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 |
| EP2311814A1 (de) | 2005-12-01 | 2011-04-20 | F. Hoffmann-La Roche AG | 2,4,5-Triphenylimidazolinderivate als Inhibitoren der Wechselwirkung zwischen P53 und MDM2-Proteinen zur Verwendung als Antikrebsmittel |
| WO2007082805A1 (en) * | 2006-01-18 | 2007-07-26 | F. Hoffmann-La Roche Ag | Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors |
| US8614192B2 (en) | 2006-07-28 | 2013-12-24 | Leiden University Medical Center | Method for treating ocular cancer |
| US8470785B2 (en) | 2006-07-28 | 2013-06-25 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| KR20090090383A (ko) | 2006-12-14 | 2009-08-25 | 다이이찌 산쿄 가부시키가이샤 | 이미다조티아졸 유도체 |
| US7625895B2 (en) * | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| MX2010003868A (es) | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| EP2224961A1 (de) * | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen |
| EP2298778A4 (de) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | Imidazothiazolderivat mit 4,7-diazaspiro[2.5]octan-ringstruktur |
| SG173028A1 (en) | 2009-01-16 | 2011-08-29 | Daiichi Sankyo Co Ltd | Imidazothiazole derivative having proline ring structure |
| KR20120099462A (ko) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 ｍｄｍ2 길항제 |
| US10159669B2 (en) * | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
| WO2012047587A2 (en) * | 2010-09-27 | 2012-04-12 | Serrata, Llc | Mdm2 inhibitors for treatment of ocular conditions |
| EP2621275B1 (de) | 2010-09-30 | 2018-03-28 | St. Jude Children's Research Hospital | Aryl-substituierte imidazole |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| MX2013005238A (es) | 2010-11-12 | 2013-09-02 | Univ Michigan | Antagonistas de mdm2 de espiro-oxindol. |
| DK2684880T3 (en) | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| BR112013028983A2 (pt) | 2011-05-11 | 2017-02-07 | Sanofi Sa | antagonistas mdm2 espiro-oxindol |
| KR101384683B1 (ko) * | 2011-10-27 | 2014-04-11 | 한국생명공학연구원 | ｍｄｍ２－결합 모티프를 포함하는 펩타이드 및 이의 용도 |
| US9937178B2 (en) | 2011-12-07 | 2018-04-10 | Duke University | Methods of identifying and using MDM2 inhibitors |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| EP3099380B1 (de) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Verfahren und zusammensetzungen zum töten von seneszenten zellen und zur behandlung von erkrankungen und störungen im zusammenhang mit seneszenz |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| TWI804010B (zh) * | 2015-08-03 | 2023-06-01 | 瑞士商諾華公司 | 作為血液學毒性生物標記之gdf-15 |
| CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CN110088081A (zh) | 2017-06-16 | 2019-08-02 | 尤尼蒂生物技术公司 | 制备用于药物用途的对映纯顺式-咪唑啉化合物的合成方法 |
| CN112236162A (zh) | 2018-04-06 | 2021-01-15 | 昂科莱奇公司 | 用于裂解选择性癌细胞的组合物 |
| EP3863720A1 (de) | 2018-10-08 | 2021-08-18 | The Regents Of The University Of Michigan | Kleinmolekülige mdm2-proteindegrader |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD201677A5 (de) * | 1980-07-25 | 1983-08-03 | Ciba Geigy | Verfahren zur herstellung von trisubstituierten imidazolderivaten |
| JPH02101065A (ja) * | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
| WO1992003421A2 (en) | 1990-08-17 | 1992-03-05 | E.I. Du Pont De Nemours And Company | Arthropodicidal pyrazolines, pyrazolidines and hydrazines |
| GB2351082A (en) * | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
-
2002
- 2002-12-09 WO PCT/EP2002/013905 patent/WO2003051360A1/en not_active Ceased
- 2002-12-09 AU AU2002361986A patent/AU2002361986B2/en not_active Ceased
- 2002-12-09 ES ES02796582T patent/ES2307822T3/es not_active Expired - Lifetime
- 2002-12-09 RU RU2004122404/04A patent/RU2312101C2/ru not_active IP Right Cessation
- 2002-12-09 CA CA002468783A patent/CA2468783A1/en not_active Abandoned
- 2002-12-09 EP EP02796582A patent/EP1463501B1/de not_active Expired - Lifetime
- 2002-12-09 JP JP2003552293A patent/JP4361798B2/ja not_active Expired - Fee Related
- 2002-12-09 AT AT02796582T patent/ATE397925T1/de not_active IP Right Cessation
- 2002-12-09 KR KR1020047009612A patent/KR100640707B1/ko not_active Expired - Fee Related
- 2002-12-09 DE DE60227108T patent/DE60227108D1/de not_active Expired - Lifetime
- 2002-12-09 BR BR0215156-1A patent/BR0215156A/pt not_active IP Right Cessation
- 2002-12-09 MX MXPA04005880A patent/MXPA04005880A/es active IP Right Grant
- 2002-12-09 PL PL02370909A patent/PL370909A1/xx not_active Application Discontinuation
- 2002-12-09 CN CNA028252292A patent/CN1604778A/zh active Pending
- 2002-12-11 US US10/316,696 patent/US6617346B1/en not_active Expired - Fee Related
- 2002-12-13 PE PE2002001225A patent/PE20030717A1/es not_active Application Discontinuation
- 2002-12-17 AR ARP020104913A patent/AR037882A1/es not_active Application Discontinuation
- 2002-12-17 UY UY27586A patent/UY27586A1/es not_active Application Discontinuation
- 2002-12-17 PA PA20028561801A patent/PA8561801A1/es unknown
- 2002-12-18 TW TW091136524A patent/TW200301696A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002361986A1 (en) | 2003-06-30 |
| TW200301696A (en) | 2003-07-16 |
| JP2005515210A (ja) | 2005-05-26 |
| AU2002361986B2 (en) | 2008-04-10 |
| KR100640707B1 (ko) | 2006-10-31 |
| PL370909A1 (en) | 2005-05-30 |
| AR037882A1 (es) | 2004-12-09 |
| CN1604778A (zh) | 2005-04-06 |
| RU2004122404A (ru) | 2005-05-27 |
| KR20040068289A (ko) | 2004-07-30 |
| PE20030717A1 (es) | 2003-08-28 |
| JP4361798B2 (ja) | 2009-11-11 |
| CA2468783A1 (en) | 2003-06-26 |
| ES2307822T3 (es) | 2008-12-01 |
| DE60227108D1 (de) | 2008-07-24 |
| UY27586A1 (es) | 2003-06-30 |
| EP1463501B1 (de) | 2008-06-11 |
| RU2312101C2 (ru) | 2007-12-10 |
| EP1463501A1 (de) | 2004-10-06 |
| PA8561801A1 (es) | 2003-07-28 |
| WO2003051360A1 (en) | 2003-06-26 |
| BR0215156A (pt) | 2004-10-19 |
| US6617346B1 (en) | 2003-09-09 |
| MXPA04005880A (es) | 2004-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397925T1 (de) | Cis-imidazoline als mdm2-hemmer | |
| DE60234125D1 (de) | E inhibitoren | |
| PT1370553E (pt) | Inibidores de rhoquinase | |
| ATE286049T1 (de) | Pyridazinonaldose reductase inhibitoren | |
| IS7138A (is) | Alkýn-arýl fosfódíesterasa-4 hindrar | |
| CY2015028I2 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
| DE60218138D1 (de) | Rho-kinase inhibitoren | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| DE60227853D1 (de) | Substituierte Pyridinylamine | |
| NO20033505D0 (no) | Cannabinoidreseptorligander | |
| PT1411764E (pt) | Cerca | |
| DK1560584T3 (da) | Fab I inhibitorer | |
| DE50206892D1 (de) | Substituierte imidazotriazinone | |
| NO20014597D0 (no) | Fremgangsmåte | |
| DK1373228T3 (da) | Substituerede fluoralkoxyphenylsulfonylurinstoffer | |
| ATE435197T1 (de) | Substituierte 4-aminocyclohexanole | |
| ITMI20010954A0 (it) | Procedimento di iodurazione | |
| NO20013535L (no) | Nöytrofil-funksjons-inhibitorer | |
| DE60217480D1 (de) | 17-METHYLEN-ANDROSTAN-3a-OL-ANALOGA ALS CRH- INHIBITOREN | |
| ATA13992002A (de) | Schlackengranulierungsanlage | |
| ITRM20010334A1 (it) | Marmitta di scarico | |
| DE60216967D1 (de) | Substituierte cyclohexanderivate | |
| AT500276B8 (de) | Radschwenksystem | |
| ATE270267T1 (de) | Scyphostatin-analoga als smase-inhibitoren | |
| DE60219659D1 (de) | Heterocyclische retioidverbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1463501 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |